Clinical Edge Journal Scan

Risk for ischemic stroke higher in seropositive RA patients


 

Key clinical point: The patients with seropositive rheumatoid arthritis (RA) are at an increased risk for ischemic stroke, particularly females and those without diabetes and dyslipidemia.

Major finding: The risk for ischemic stroke was significantly higher in the seropositive RA vs. control group (adjusted hazard ratio [aHR], 1.40; 95% confidence interval, 1.07-1.82). The risk for ischemic stroke was higher in females with seropositive RA vs. males (aHR, 1.44 vs. 1.12; P less than .001) and those without vs. with diabetes (aHR, 1.47 vs. 0.98; P less than .001) and dyslipidemia (aHR, 1.43 vs. 0.92; P = .008).

Study details: This was a nationwide, longitudinal 12-year follow-up study involving patients with seropositive RA (n=2,765) who were prescribed any disease-modifying antirheumatic drug and age- and sex-matched with control participants (n=13,825).

Disclosures: This study was funded by the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Science, ICT, and Future Planning. The authors declared no conflicts of interest.

Source: Lee DH et al. PLoS One. 2021 May 17. doi: 10.1371/journal.pone.0251851 .

Recommended Reading

Clinical Edge Commentary: RA June 2021
MDedge Rheumatology
RA: Tofacitinib modified-release 11 mg OD plus methotrexate shows promise in ORAL Shift trial
MDedge Rheumatology
Worse COVID-19 outcomes in RA patients treated with rituximab and JAKi
MDedge Rheumatology
Additional cardiovascular benefits of methotrexate in RA
MDedge Rheumatology
Tocilizumab raises risk of diverticulitis and GI perforation vs. rituximab and abatacept in RA
MDedge Rheumatology
Variation in risk profiles of early RA treatment regimens
MDedge Rheumatology
Early glucocorticoids bridging reduces chronic NSAID and analgesic use in early RA patients with a favorable prognosis
MDedge Rheumatology
HR-pQCT scanning has comparable diagnostic precision to conventional radiography for classifying erosive RA
MDedge Rheumatology
Clusterin could serve as a potential predictive biomarker for disease activity and treatment response in early RA
MDedge Rheumatology
Baricitinib shows long-term promise in treatment-refractory RA
MDedge Rheumatology